|4Apr 26, 6:36 PM ET

RXi Pharmaceuticals Corp 4

4 · RXi Pharmaceuticals Corp · Filed Apr 26, 2017

Insider Transaction Report

Form 4
Period: 2017-04-24
Dispersyn Gerrit
Chief Development Officer
Transactions
  • Award

    Stock option (right to buy)

    2017-04-24+95,00095,000 total
    Exercise: $0.65Exp: 2027-04-24Common stock (95,000 underlying)
Footnotes (1)
  • [F1]The stock option vests in equal monthly installments over four years beginning on the first monthly anniversary of the grant date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION